Merck: launch of four pivotal phase 3 trials
These global studies involve:
- Bomedemstat, being evaluated for the treatment of selected patients with essential thrombocythemia (ET);
- Nemtabrutinib, being evaluated for the treatment of selected patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL);
- MK-2870, under evaluation for certain patients with non-small cell lung cancer (NSCLC) and certain patients with previously treated endometrial carcinoma;
- MK-5684,under evaluation for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC).
' These Phase 3 trial launches for four of our investigational candidates represent a critical milestone in our efforts to advance potential treatment options for people with solid tumors and hematological neoplasms and malignancies, ' said Dr. Marjorie Green, Senior Vice President and Head of Global Oncology Development at Merck Research Laboratories.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction